LONDON - Aptamer Group plc (AIM: APTA), a developer of Optimer® binders for the life sciences industry, disclosed that Dr. Adam Hargreaves (LON:HRGV), the Non-Executive Chairman, has increased his stake in the company. On Monday, Dr. Hargreaves purchased 19,545,972 ordinary shares at a price of 0.31 pence each on the London Stock Exchange (LON:LSEG).
Following this transaction, Dr. Hargreaves now holds a total of 137,045,972 ordinary shares, which equates to approximately 6.9% of Aptamer's issued share capital. The purchase is a significant increase in his beneficial interest in the company, signaling a strong vote of confidence from the Non-Executive Chairman in the firm's prospects.
Aptamer Group specializes in the development of Optimer® binders, which are designed to offer advantages over traditional antibodies in various applications within the life sciences sector. The company's shares are publicly traded on the AIM market of the London Stock Exchange.
The transaction was conducted in accordance with the UK Market Abuse Regulation, which requires detailed disclosure of share dealings by directors and other persons discharging managerial responsibilities (PDMRs). Such regulations are intended to ensure transparency in the financial activities of company insiders, providing investors and the public with relevant information.
This announcement comes directly from a press release statement issued by Aptamer Group plc and is presented without any additional commentary or speculation. The disclosure provides investors and the market with transparent information about the dealings of a key company insider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.